TamaBio aims to provide optimal
solutions for
patients through
product development using
cutting-edge technology.
TamaBio will be exhibiting the pericardial membrane PeriBeam® at the 77th Annual Scientific Meeting of the Japanese Association for Thoracic Surgery (at Kanazawa City, Ishikawa Japan).
ISO13485:2016 was maintained : based on the evaluation from the regular audit.
The sterilization expiration date of the Dura Mater Substitute “DuraBeam®” has been extended to three (3) years.
We will be sponsoring the 48th Japanese Society of Neurotraumatology (Feb.21st (Fri) – Feb.22nd (Sat), 2025).
We exhibited a booth at the Japan Neurosurgical Society 67th Tohoku Branch Meeting.
TamaBio has been granted patents in Japan for three innovative regenerative medical devices it is developing.
We will be sponsoring the Kyushu University Neurosurgery Annual Report.
Ion Irradiated ePTFE Sheet
DuraBeam®︎
Dura Mater Substitute 
Dura Mater Substitute - Classification
Highly-regulated medical device (Class IV)
- Purpose of use/effect
Brain dura mater replacement and substitution
- Sizes
120mm×120mm,100mm×100mm,
100mm×50mm,50mm×50mm- Thickness
0.30mm(300μm)
Medical device approval number: 22900BZX00291000
Ion Irradiated ePTFE Sheet
PeriBeam®︎
Pericardial Membrane 
Pericardial Membrane - Classification
Highly-regulated medical device (Class IV)
- Purpose of use/effect
Pericardial replacement and substitution
- Sizes
120mm×120mm,100mm×100mm
- Thickness
0.09mm(90μm)
Medical device approval number: 23000BZX00360000
TamaBio : Contributing to medical care through innovative technology
TamaBio was established in April 2016 using RIKEN, the National Research and Development Agency’s special processing technology for polymer resin as a practical basic technology . TamaBio has so far obtained manufacturing and sales approval (Class IV) from the Ministry of Health, Labor and Welfare for the Dura Mater Substitute “DuraBeam®” and the Pericardial Membrane “PeriBeam®” , and has obtained core patents in Japan, The United States, The People’s Republic of China, and Taiwan. The Products are distributed by major medical equipment distribution companies. TamaBio’s synthetic artificial biomembranes have been used clinically in thousands of surgeries to date, and the number of uses is expanding.
- Company name
- TamaBio Company Limited
- Established
- 2016/4/21
- Head Office
- 402 Gran Creste 2-2-18 Sakai Musashino-shi Tokyo 180-0022 Japan
- Business
- Medical device manufacturing / Class 1 manufacturing and sales Development, manufacturing, and sales of Class IV highly controlled medical devices (dura mater and pericardial prosthesis material) Development, manufacturing, and sales of regenerative medical devices and other synthetic artificial biomembranes.
- Managing
Director / CEO - Tetsuya Nagao
- TEL / FAX
- TEL : +81-422-53-5051
/ FAX : +81-422-38-5091
TamaBio is promoting the development of Dura Mater Substitute “DuraBeam®︎”, Pericardial Membrane “PeriBeam®︎”, and artificial organs and regenerative medicine technologies in more critical and promising fields. Medical devices such as implants are being developed around the world as functional substitutes for patients’ lost organs, but in clinical settings, various adverse events such as postoperative infections, adhesion with self-tissue, and calcification due to long-term use are issues. TamaBio products are highly biocompatible, and we will overcome these issues through our processing technology and continue to work to deliver newly developed products to patients.
Research results are born every day. We would like doctors, researchers, investors, distributors, experts, and managers to participate in TamaBio and deliver cutting-edge technology to the world and to patients.
Managing Director / CEO
Tetsuya Nagao
Tetsuya Nagao
